"MFSI continues to build a strong intellectual property base in the area of biological sample collection, processing, and detection," Dr. M. Allen Northrup, MFSI President and CEO said. "We have built a repertoire of proprietary technology, expertise and capabilities as exemplified by these new patents," he added.
Microfluidic Systems (MFSI), www.microfluidicsystems.com, was founded in 2001 and is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. MFSI personnel have been involved with the development of automated DNA-based pathogen detection systems and microfluidics for the US Government and commercial markets for over 25 years, including the world's first miniaturized, portable, battery-operated, real-time, polymerase-chain-reaction (PCR)-based detection system. For more information, please contact MFSI at 510-354-0400 or visit the website, www.microfluidicsystems.com.
M. Allen Northrup Ph.D. | |
CEO and Chief Technology Officer | |
MicroFluidic Systems | |
47790 Westinghouse Dr | |
Fremont, CA 94539 | |
510-354-0400 ext 201 | |
510-354-0404 (fax) | |
SOURCE Microfluidic Systems